These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 30398481)

  • 1. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia.
    Cases A; Gorriz JL
    Drugs Today (Barc); 2018 Oct; 54(10):601-613. PubMed ID: 30398481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y; Xu R; Wang F; Liu Y; Xu J; Zhao N; Cheng F; Long L; Jia J; Lin S
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1057-1066. PubMed ID: 33459923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.
    Spinowitz BS; Fishbane S; Pergola PE; Roger SD; Lerma EV; Butler J; von Haehling S; Adler SH; Zhao J; Singh B; Lavin PT; McCullough PA; Kosiborod M; Packham DK;
    Clin J Am Soc Nephrol; 2019 Jun; 14(6):798-809. PubMed ID: 31110051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C; Nassar T; Qunibi W
    Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
    Tamargo J; Caballero R; Delpón E
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
    Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
    J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.
    Packham DK; Kosiborod M
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):567-73. PubMed ID: 26998854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N; Nishio T; Osonoi T; Saka Y; Imasawa T; Ohtake T; Mizuno H; Shibagaki Y; Kim H; Yajima T; Sarai N
    Clin Exp Nephrol; 2020 Dec; 24(12):1144-1153. PubMed ID: 32779057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
    Schaefer JA; Gales MA
    Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
    Rafique Z; Peacock WF; LoVecchio F; Levy PD
    Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
    Kosiborod M; Rasmussen HS; Lavin P; Qunibi WY; Spinowitz B; Packham D; Roger SD; Yang A; Lerma E; Singh B
    JAMA; 2014 Dec; 312(21):2223-33. PubMed ID: 25402495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia.
    Fishbane S; Ford M; Fukagawa M; McCafferty K; Rastogi A; Spinowitz B; Staroselskiy K; Vishnevskiy K; Lisovskaja V; Al-Shurbaji A; Guzman N; Bhandari S
    J Am Soc Nephrol; 2019 Sep; 30(9):1723-1733. PubMed ID: 31201218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of sodium zirconium cyclosilicate for hyperkalemia among patients with chronic kidney disease or heart failure in Kuwait.
    Elsisi GH; Mahmoud MMI; Al-Humood K; Al-Yousef A
    J Med Econ; 2024; 27(1):253-265. PubMed ID: 38318718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF; Rafique Z; Vishnevskiy K; Michelson E; Vishneva E; Zvereva T; Nahra R; Li D; Miller J
    Acad Emerg Med; 2020 Jun; 27(6):475-486. PubMed ID: 32149451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
    Palmer BF
    Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study.
    Dwyer JP; Agiro A; Desai P; Oluwatosin Y
    Adv Ther; 2023 Nov; 40(11):4777-4791. PubMed ID: 37606716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.
    Yoo N; Song YB; Dubinsky I; Altshuler J
    Ann Pharmacother; 2023 Sep; 57(9):1044-1052. PubMed ID: 36637028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HARMONIZE Asia: A Phase III Randomized Study to Investigate the Efficacy and Safety of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China.
    Liang X; Lu W; Yu X; Cheng H; He Q; Peng Q; Ni Z; Long G; Wang L; Chen W; Li R; Zhao J; Zhang Y; Lisovskaja V; Tang Z
    Clin Ther; 2024 Sep; 46(9):702-710. PubMed ID: 39112102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia.
    Imamura T; Oshima A; Narang N; Ushijima R; Ueno Y; Ueno H; Kinugawa K
    Intern Med; 2021; 60(13):2093-2095. PubMed ID: 34193775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.